Clinical trials: Phosphorus Metabolism Disorders
Hyperphosphatemia
Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
Primary Objective: To demonstrate efficacy of Renvela tablets in the reduction of serum phosphorus in hyperphosphatemia in participants with chronic kidney disease not on dialysis.
- Trial name
- RECOVER (NCT03001011)
- Testing
- Sevelamer Carbonate (GZ419831)
- Where
- 38 sites in China
- Volunteers
- 202 people
- Sponsor
- Sanofi
Hyperphosphataemia
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.
- Trial name
- NCT02151643
- Testing
- PT20
- Volunteers
- 153 people
- Sponsor
- Phosphate Therapeutics
Hypophosphatemic Rickets
Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts
Fibroblast growth factor 23 (FGF23) is the cornerstone of phosphate / calcium / vitamin D metabolism: it is synthesized mainly by osteocytes and acts as a Phosphating agent, inhibitor of dihydroxyvitamin D, and inhibitor of…
- Trial name
- HYPO-CLASTE (NCT04184661)
- Testing
- blood sample
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Hospices Civils de Lyon
Hyperphosphatemia
Long-term Effect of Lanthanum Carbonate on Bone
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an…
- Trial name
- NCT00557323
- Testing
- Lanthanum carbonate
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- Shire
Hyperphosphatemia
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat…
- Trial name
- NCT02675998
- Testing
- Tenapanor
- Where
- 32 sites in United States
- Volunteers
- 219 people
- Sponsor
- Ardelyx
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
Hyperphosphataemia, ESRD
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
The objective of this non-interventional study is to confirm that with standard OsvaRen® treatment it is possible to achieve in at least 60% of the patients the levels of phosphorus, total calcium, and iPTH seen in the CALMAG…
- Trial name
- Steering (NCT01424787)
- Where
- 24 sites in Denmark, Germany and 2 more
- Volunteers
- 324 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
Expanded Access to Burosumab
Individual patient expanded access requests may be considered for patients who have no other treatment options
- Trial name
- NCT03775187
- Testing
- Burosumab
- Sponsor
- Kyowa Kirin Co., Ltd.
Phosphate Deficiency, Phosphate Overload
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism
The goal of this observational study is to create, manage and analyze a multicenter national database of patients affected by diseases of phosphate metabolism, aimed at collecting and studying anamnestic, diagnostic, genetic…
- Trial name
- NCT06826664
- Where
- 28 sites in Italy
- Volunteers
- 100 people
- Sponsor
- F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Hypophosphatemia, Hypophosphatemic Rickets
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
A 52 week, open label trial to assess the safety and efficacy of KRN23, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome(ENS) and associated hypophosphatemic rickets A 26 weeks…
- Conditions
- Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
- Trial name
- NCT03581591
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Redwood Dermatology Sciences
X-linked Hypophosphatemia
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
- Trial name
- NCT01571596
- Testing
- KRN23
- Where
- 6 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia, Chronic Kidney Disease
Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia
The phosphorus content in saliva is increased in chronic kidney disease. We hypothesize that a chewing gum that binds salivary phosphorus would be a novel, effective agent to reduce serum levels of phosphorus in patients with…
- Trial name
- NCT01057108
- Testing
- FOSTRAP Chewing Gum
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Denver Nephrologists, P.C.
Chronic Kidney Disease, Hyperphosphatemia
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia…
- Conditions
- Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
- Trial name
- 05D (NCT02492620)
- Testing
- Ferric Citrate
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Denver Nephrologists, P.C.
End Stage Renal Disease, Kidney Failure
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial.
- Conditions
- End Stage Renal Disease, Kidney Failure, Renal Failure, Hyperphosphatemia
- Trial name
- NCT01554982
- Testing
- ferric citrate
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 168 people
- Sponsor
- Keryx Biopharmaceuticals
Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis
Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal
- Trial name
- NCT02510274
- Testing
- ASP3325
- Where
- 5 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease, Dialysis
A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia
This study consists of a 4 week run-in period with a Ca based phosphate binder and 12 weeks treatment period by MCI-196 or placebo, (both on Ca based phosphate binder).
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00451295
- Testing
- MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)
- Where
- 25 sites in Czechia, France and 8 more
- Volunteers
- 6 people
- Sponsor
- Tanabe Pharma Corporation
Hypophosphatemic Rickets, X-Linked Dominant
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH).
- Trial name
- NCT00195936
- Testing
- Cinacalcet
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Children's Mercy Hospital Kansas City
Hypophosphatemic Rickets, Growth Disorders
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
X-linked hypophosphatemic rickets (XLH) is characterized by rickets, disproportionate short stature, impaired renal phosphate reabsorption and vitamin D metabolism.
- Conditions
- Hypophosphatemic Rickets, Growth Disorders, Somatropin Therapy
- Trial name
- NCT00473187
- Testing
- somatropin
- Where
- Germany
- Sponsor
- University of Rostock
AV Fistula
av Fistula Patency Loss as a Cause of Fistula Failure and Hyperphosphatemia
Assessment of arteriovenous fistula patency loss which leads to av fistula failure and its relation to high serum phosphate level in chronic hemodialysis patients.
- Trial name
- NCT05569109
- Testing
- doppler ultrasound
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
Malnutrition
Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.
Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D).
- Trial name
- IPSAASU (NCT02812134)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens